Evan R. Delgado

Evan R. Delgado

Auto-generated profile, based on publicly available information

Evan R. Delgado

Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2019 in Hepatology
Verified
Journal Article
Closed access
PDF file
PWPatrick D. Wilkinson
Patrick D. Wilkinson
EDEvan R. Delgado
Evan R. Delgado
FAFrances Alencastro
Frances Alencastro
MLMadeleine P. Leek
Madeleine P. Leek
NRNairita Roy
Nairita Roy
ADAndrew W. Duncan
Andrew W. Duncan

26 March 2016 in Hepatology
Verified
Journal Article
Open access
PDF file
SHShu-hao Hsu
Shu-hao Hsu
EDEvan R. Delgado
Evan R. Delgado
POP. Anthony Otero
P. Anthony Otero
KTKun‐Yu Teng
Kun‐Yu Teng
HKHuban Kutay
Huban Kutay
ADAndrew W. Duncan
Andrew W. Duncan
A defining feature of the mammalian liver is polyploidy, a numerical change in the entire complement of chromosomes. The first step of polyploidization involves cell division with failed cytokinesis. Although polyploidy is common, affecting ∼90% of hepatocytes in mice and 50% in humans, the specialized role played by polyploid cells in liver homeostasis and disease remains poorly understood. The goal of this study was to identify novel signals that regulate polyploidization, and we focused on microRNAs (miRNAs). First, to test whether miRNAs could regulate hepatic polyploidy, we examined livers from Dicer1 liver‐specific knockout mice, which are devoid of mature miRNAs. Loss of miRNAs resulted in a 3‐fold reduction in binucleate hepatocytes, indicating that miRNAs regulate polyploidization. Second, we surveyed age‐dependent expression of miRNAs in wild‐type mice and identified a subset of miRNAs, including miR‐122, that is differentially expressed at 2‐3 weeks, a period when extensive polyploidization occurs. Next, we examined Mir122 knockout mice and observed profound, lifelong depletion of polyploid hepatocytes, proving that miR‐122 is required for complete hepatic polyploidization. Moreover, the polyploidy defect in Mir122 knockout mice was ameliorated by adenovirus‐mediated overexpression of miR‐122, underscoring the critical role miR‐122 plays in polyploidization. Finally, we identified direct targets of miR‐122 (Cux1, Rhoa, Iqgap1, Mapre1, Nedd4l, and Slc25a34) that regulate cytokinesis. Inhibition of each target induced cytokinesis failure and promoted hepatic binucleation. Conclusion: Among the different signals that have been associated with hepatic polyploidy, miR‐122 is the first liver‐specific signal identified; our data demonstrate that miR‐122 is both necessary and sufficient in liver polyploidization, and these studies will serve as the foundation for future work investigating miR‐122 in liver maturation, homeostasis, and disease. (Hepatology 2016;64:599‐615)

1 June 2019 in The American Journal of Pathology
Verified
Journal Article
Closed access
PWPatrick D. Wilkinson
Patrick D. Wilkinson
FAFrances Alencastro
Frances Alencastro
EDEvan R. Delgado
Evan R. Delgado
MLMadeleine P. Leek
Madeleine P. Leek
MWMatthew P. Weirich
Matthew P. Weirich
ADAndrew W. Duncan
Andrew W. Duncan

1 February 2020 in The American Journal of Pathology
Verified
Journal Article
Closed access
ESElizabeth C. Stahl
Elizabeth C. Stahl
EDEvan R. Delgado
Evan R. Delgado
FAFrances Alencastro
Frances Alencastro
SLSamuel T. LoPresti
Samuel T. LoPresti
PWPatrick D. Wilkinson
Patrick D. Wilkinson
BBBryan N. Brown
Bryan N. Brown

1 October 2013 in Current Cancer Drug Targets
Verified
Journal Article
Open access
PDF file
EDEvan Delgado
Evan Delgado
RBRaman Bahal
Raman Bahal
JYJing Yang
Jing Yang
JLJung M. Lee
Jung M. Lee
DLDanith H Ly
Danith H Ly
SMSatdarshan P. S. Monga
Satdarshan P. S. Monga
Hepatocellular cancer (HCC) is the third cause of death by cancer worldwide. In the current study we target β- catenin, an oncogene mutated and constitutively active in 20-30% of HCCs, via a novel, cell permeable gamma guanidine-based peptide nucleic acid (γGPNA) antisense oligonucleotide designed against either the transcription or the translation start site of the human β-catenin gene. Using TOPflash, a luciferase reporter assay, we show that γGPNA targeting the transcription start site showed more robust activity against β-catenin activity in liver tumor cells that harbor β-catenin gene mutations (HepG2 & Snu-449). We identified concomitant suppression of β-catenin expression and of various Wnt targets including glutamine synthetase (GS) and cyclin-D1. Concurrently, γGPNA treatment reduced proliferation, survival and viability of HCC cells. Intriguingly, an angiogenesis quantitative Real-Time-PCR array identified decreased expression of several pro-angiogenic secreted factors such as EphrinA1, FGF-2, and VEGF-A upon β-catenin inhibition in liver tumor cells. Conversely, transfection of stabilized-β-catenin mutants enhanced the expression of angiogenic factors like VEGF-A. Conditioned media from HepG2 cells treated with β-catenin but not the mismatch γGPNA significantly diminished spheroid and tubule formation by SK-Hep1 cells, an HCC-associated endothelial cell line. Thus, we report a novel class of cell permeable and efficacious γGPNAs that effectively targets β-catenin, a known oncogene in the liver. Our study also identifies a novel role of β-catenin in liver tumor angiogenesis through paracrine mechanisms in addition to its roles in proliferation, survival, metabolism and cancer stem cell biology, thus further strengthening its effectiveness as a therapeutic target in HCC.

1 July 2014 in The American Journal of Pathology
Verified
Journal Article
Open access
EDEvan R. Delgado
Evan R. Delgado
JYJing Yang
Jing Yang
JSJuhoon So
Juhoon So
MFMaura Fanti
Maura Fanti
SLStephanie Leimgruber
Stephanie Leimgruber
SMSatdarshan P. S. Monga
Satdarshan P. S. Monga
Hepatocellular carcinoma (HCC), the third most common cause of cancer-related deaths worldwide, lacks effective medical therapy. Large subsets of HCC demonstrate Wnt/β-catenin activation, making this an attractive therapeutic target. We report strategy and characterization of a novel small-molecule inhibitor, ICG-001, known to affect Wnt signaling by disrupting β-catenin-CREB binding protein interactions. We queried the ZINC online database for structural similarity to ICG-001 and identified PMED-1 as the lead compound, with ≥70% similarity to ICG-001. PMED-1 significantly reduced β-catenin activity in hepatoblastoma and several HCC cells, as determined by TOPflash reporter assay, with an IC50 ranging from 4.87 to 32 μmol/L. Although no toxicity was observed in primary human hepatocytes, PMED-1 inhibited Wnt target expression in HCC cells, including those with CTNNB1 mutations, and impaired cell proliferation and viability. PMED-1 treatment decreased β-catenin-CREB binding protein interactions without affecting total β-catenin levels or activity of other common kinases. PMED-1 treatment of Tg(OTM:d2EGFP) zebrafish expressing GFP under the β-catenin/Tcf reporter led to a notable decrease in β-catenin activity. The PMED effect on β-catenin signaling lasted from 12 to 24 hours in vitro and 6 to 15 hours in vivo. Thus, using a rapid and cost-effective computational methodology, we have identified a novel and specific small-molecule inhibitor of Wnt signaling that may have implications for HCC treatment.